With the deepening of the reform of its pharmaceutical industry in the past few years, since joining the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), China has added or amended more and more laws and regulations to meet the needs of the world’s drug developers. During DIA China 2019 […]
2018 regulatory approvals tackling unmet medical needs
Major improvements in the regulatory environment as well as changes in strategies of multinational companies have led to a general decrease in the time to marketing authorization, improved consistency, as well as an increase in the number of medicines that have become available over the last decade, 2009-2018, across six major regulatory agencies. These are […]
Fatty liver disease, NASH surge amid global obesity epidemic
Non-alcoholic fatty liver disease and the more severe form of this disease called non-alcoholic steatohepatitis, or NASH, are two increasingly prevalent diseases characterized by the progressive accumulation of fat or triglycerides within the liver. This accumulation occurs in the absence of excessive alcohol consumption. It can lead to inflammation, oxidative damage and the development of […]
Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019
Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023, according to Cortellis Drugs to Watch 2019, from Clarivate Analytics. Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan […]
Busy biopharma M&A activity closed out 2018
During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]
Biopharma licensing finished with a strong Q4
During the fourth quarter of 2018, Cortellis Competitive Intelligence registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]
In multiple myeloma, B-cell maturation antigen emerges as promising target
This is a Cortellis Market Insight report, an ongoing series featuring expert reviews of hot topics in the biopharma field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis were gathered from Cortellis from Clarivate Analytics. There remains an unmet need for patients with multiple myeloma (MM), particularly […]
Med-tech’s feverish investment outpaces biopharma
In every type of financing, from IPOs and follow-on public offerings to private placements and venture capital rounds, the med-tech industry produced more money and completed more financings in 2018 than the prior year, reflecting the same significant jump in activity seen with its biopharma counterpart. What is different, however, is that med tech experienced […]
Biopharma M&A engine fires up as new year rings in big deals
Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the initial […]
Biopharma M&A engine fires up as new year rings in big deals
Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the […]
